Charts
26 Apr, 2024
25 Apr, 2024
24 Apr, 2024
23 Apr, 2024
22 Apr, 2024
21 Apr, 2024
20 Apr, 2024
19 Apr, 2024
18 Apr, 2024
17 Apr, 2024
16 Apr, 2024
15 Apr, 2024
News
16 Apr, 2024
12:30
Yahoo! Finance
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are excited that our abstracts focused on XEN1101, including interim data from the ongoing X-TOLE open-label extension st
10 Apr, 2024
12:30
Yahoo! Finance
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024. Company Presentation Details:Date: Tuesday, April 16, 2024Time: 9:30 AM Eastern TimeWebcast: Register herePresenters: Ian Mortimer, President and Chief Executive Officer A live webcast of the company present
04 Apr, 2024
20:01
Yahoo! Finance
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 23rd Annual Needham (Virtual) Healthcare Conference taking place April 8-11, 2024. Company Fireside Chat Presentation Details: Date:Thursday, April 11, 2024 Time:3:00 PM Eastern Time Webcast:Register here Presenters:Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financ
20 Mar, 2024
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $21.08 per unit.
19 Mar, 2024
10:16
Yahoo! Finance
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
12 Mar, 2024
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event. Company Fireside Chat Presentation Details: Date:Tuesday, March 19, 2024 Time:12:30-12:55 PM Eastern Time Webcast:Register here Presenters: Sherry Aulin, Chief Financial Officer Chris Von Seggern, Chief Commercial Officer A live webcast of the company presen
09 Mar, 2024
04:55
Yahoo! Finance
Xenon Pharmaceuticals Inc (NASDAQ:XENE), a clinical-stage biopharmaceutical company, focuses on developing therapeutics to improve the lives of patients with neurological disorders.
05 Mar, 2024
21:01
Yahoo! Finance
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024. Company Fireside Chat Presentation Details: Date:Monday, March 11, 2024 Time:11:20 AM Eastern Time Webcast:Register here Presenters:Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chie
02 Mar, 2024
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript February 29, 2024 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.64, expectations were $-0.76. Xenon Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name […]
01 Mar, 2024
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
29 Feb, 2024
21:34
Yahoo! Finance
Advances in Epilepsy and Depression Programs Highlighted Amid Financial Growth
21:01
Yahoo! Finance
XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025 Planned “end-of-Phase 2” meeting with the FDA in April to support the initiation of XEN1101 Phase 3 program in major depressive disorder in the second half of the year Strong financial position with approximately $930 million to fully support XEN1101 Phase 3
Companies Reporting Before The Bell
• Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on ...
28 Feb, 2024
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Here's what investors ...
22 Feb, 2024
21:01
Yahoo! Finance
VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2023 financial and operating results after the close of U.S. financial markets on Thursday, February 29, 2024. Conference Call/Webcast Information: Date: Thursday, February 29, 2024Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)Dial-In: (800) 715-9871 or (646) 307-1963 for internat
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
The post 3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition appeared first on InvestorPlace.
More From InvestorPlace
ChatGPT IPO Could Shock the World, Make This Move Before the Announcement
Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
16 Feb, 2024
RBC Capital Marketshas initiatedBiohaven Ltd(NYSE:BHVN), noting optimizeddevelopment across programs.
The ...
08 Feb, 2024
07 Feb, 2024
Key Insights Using the 2 Stage Free Cash Flow to Equity, Xenon Pharmaceuticals fair value estimate is US$78.72 Current...
23 Jan, 2024
Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.
19 Jan, 2024
14:55
Yahoo! Finance
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
08 Jan, 2024
Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024 XEN1101 Phase 3 Program in Major Depressive Disorder Planned for Initiation in 2024 VANCOUVER, British Columbia, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined progress within its pipeline programs and key milestones for 2024. Mr. Ian Mortimer, Xenon’s President and Chief Ex
03 Jan, 2024
13:30
Yahoo! Finance
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024. Company Presentation Details: Date:Monday, January 8, 2024 Time:9-9:40 AM Pacific Time (12-12:40 PM Eastern Time) Presenter:Ian Mortimer, President and Chief Executive Officer, Xenon Pharmac
08 Dec, 2023
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:
Bullish
Somewhat ...
04 Dec, 2023
21:16
Yahoo! Finance
VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares. The common shares were offered at a public offering
11:30
Yahoo! Finance
Key Insights Significantly high institutional ownership implies Xenon Pharmaceuticals' stock price is sensitive to...
30 Nov, 2023
Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon.The company announced the ...
29 Nov, 2023
28 Nov, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades ...
27 Nov, 2023
19:10
FinancialContent
Monday,Xenon Pharmaceuticals Inc(NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, ...
18:41
FinancialContent
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter ...
Biotech stock Xenon rocketed Monday, after its experimental epilepsy drug unexpectedly showed promise in depression treatment.
Xenon Pharmaceuticals Inc(NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated ...
15:17
FinancialContent
U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday.
Shares of Ituran Location and Control Ltd. ...
13:30
FinancialContent
Xenon Pharmaceuticals shares fell early Monday after the company released new clinical-trial data on an experimental depression treatment.
26 Nov, 2023
17 Nov, 2023
Investors in Xenon Pharmaceuticals Inc (XENE) saw new options become available this week, for the July 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
16 Nov, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $19.19 per unit.
10 Nov, 2023
Thursday,Neurocrine Biosciences Inc(NASDAQ: NBIX)releasedPhase 2 study results from two signal-seeking pipeline ...
09 Nov, 2023
08 Nov, 2023
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:01 PM.
Here's what investors ...
Companies Reporting Before The Bell
• Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
• ...
07 Nov, 2023
06 Nov, 2023
13 Aug, 2023
10 Aug, 2023
09 Aug, 2023
08 Aug, 2023
24 Jul, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $18.57 per unit.
17 Jul, 2023
Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter:
Bullish
Somewhat ...
15 Jun, 2023
Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat ...
23 May, 2023
13 May, 2023
09 May, 2023
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:01 PM.
Here's what investors need to ...
Companies Reporting Before The Bell
• Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on ...
08 May, 2023
25 Apr, 2023
Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter:
Bullish
Somewhat ...
18:27
FinancialContent
Cantor Fitzgerald has initiated coverage onXenon Pharmaceuticals Inc(NASDAQ: XENE) with an Overweight rating and ...
Upgrades
Erste Group upgraded the previous rating for NVIDIA Corp (NASDAQ:NVDA) from Hold to Buy. In the fourth quarter, NVIDIA showed ...
13:10
FinancialContent
General Motors (GM) - Shares traded about 3% higher Tuesday morning following better-than-expected Q1 earnings ...
11 Apr, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $18.18 per unit.
15 Mar, 2023
02 Mar, 2023
01 Mar, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue ...
28 Feb, 2023
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Wednesday, 2023-03-01. Here's what investors ...
23 Feb, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $42.13 per unit.
08 Feb, 2023
03 Feb, 2023
02 Feb, 2023
17:52
FinancialContent
Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.
31 Jan, 2023
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings:
Bullish
Somewhat ...
12 Jan, 2023
A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies.
23 Dec, 2022
14 Dec, 2022
Upgrades
Wolfe Research upgraded the previous rating for EQT Corp (NYSE:EQT) from Peer Perform to Outperform. EQT earned $1.04 in the ...
12 Dec, 2022
Upgrades
For Colliers International Group Inc (NASDAQ:CIGI), Goldman Sachs upgraded the previous rating of Neutral to Buy. Colliers Intl ...
06 Dec, 2022
Benzinga Pro data, Xenon Pharmaceuticals (NASDAQ:XENE) reported Q3 sales of $132 thousand. Earnings fell to a loss of $37.15 million, ...
29 Nov, 2022
A Relative Strength Rating upgrade for Xenon Pharmaceuticals shows improving technical performance.
28 Nov, 2022
Upgrades
Barclays upgraded the previous rating for PerkinElmer Inc (NYSE:PKI) from Underweight to Equal-Weight. For the third quarter, ...
23 Nov, 2022
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $18.18 per unit.
09 Nov, 2022
Emergent BioSolutions led a decline for biotech stocks on Wednesday as EBS stock tumbled on declining sales and a delayed contract.
08 Nov, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue ...
07 Nov, 2022
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors ...
